Metabolic effects of chronic dihydronicotinamide riboside (NRH) administration in mice - RNA-seq of murine tissues (NRH treatment)
Ontology highlight
ABSTRACT: NAD+ is a crucial cofactor for the activity of various enzymes, including sirtuins and ADP-ribosyl transferases, and its decline is associated with aging and metabolic-related diseases. Therefore, a strong interest has been raised in the therapeutic use of NAD+ precursors (Vitamin B3s), but many suffer from poor bioavailability and adverse effects. This study characterizes the metabolic impact of dihydronicotinamide riboside, a recently identified novel form of NAD+ precursor. Upon oral administration in mice, NRH reaches all tissues examined. Chronic administration in low-fat diet-fed mice showed negligible metabolic effects, while high-fat diet-fed mice were protected against body weight gain and glucose intolerance. However, our study also unveiled potential side effects at higher doses. Thus, NRH could constitute an alternative NAD+ boosting strategy to prevent diet-induced metabolic complications and conditions associated with low NAD+ levels, but the therapeutic window must be optimized to maximize benefits and minimize risks. Mice were either low-fat diet fed or high-fat diet-fet, and either in control group or supplemented with NRH groups (NRH100 and NRH400) for up to 16 weeks. Tissues were collected to extract RNA and perform RNA-seq (BRB-seq protocol)
INSTRUMENT(S): Illumina NovaSeq 6000
ORGANISM(S): Mus musculus
SUBMITTER: Marie Rumpler
PROVIDER: E-MTAB-14195 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA